Evommune, Inc. - 8-K Filing
Evommune announced that its Phase 2b trial of EVO756 in moderate-to-severe chronic spontaneous urticaria (CSU) did not meet the primary endpoint, leading to a decision to cease development for this indication. The trial enrolled 160 patients across four regions and evaluated three active dose regimens versus placebo over 12 weeks. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $EVMN